Oxidative stress in cardiovascular disease: Molecular basis of its deleterious effects, its detection, and therapeutic considerations

Current Opinion in Cardiology

Volumn 19, Issue 5, 2004, Pages 488-493

  Molavi, Behzad ^a   Mehta, Jawahar L ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Atherosclerosis; Cardiac lipotoxicity; Congestive heart failure; Oxidative stress; Reactive oxygen species

Indexed keywords

ANTIOXIDANT; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; XANTHINE OXIDASE;

ACUTE HEART INFARCTION; ATHEROGENESIS; CARDIAC LIPOTOXICITY; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; ENDOTHELIUM LESION; HUMAN; LIPID STORAGE; MOLECULAR DYNAMICS; MORBIDITY; MORTALITY; NUCLEAR MAGNETIC RESONANCE; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; URINALYSIS;

ACUTE DISEASE; ANTIOXIDANTS; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; MYOCARDIAL REPERFUSION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 4544385468     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hco.0000133657.77024.bd     Document Type: Review

References (26)

1. Griendling KKP, FitzGerald GAM: Oxidative stress and cardiovascular injury: part i: basic mechanisms and in vivo monitoring of ROS. Circulation 2003, 108:1912-1916. This is an excellent review of the metabolic pathways involved in ROS generation and methods of its quantification.
2. Taniyama Y, Griendling KK: Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 2003, 42:1075-1081. This is a thorough description of deleterious effects of ROS on vasculature, examining the details of such events in every layer of the vessel wall.
3. Mugge A, Elwell JH, Peterson TE, et al.: Chronic treatment with polyethylene-glycolated superoxide dismutase partially restores endothelium-dependent vascular relaxations in cholesterol-fed rabbits. Circ Res 1991, 69:1293-1300.
4. Dimmeler S, Zeiher AM: Reactive oxygen species and vascular cell apoptosis in response to angiotensin II and pro-atherosclerotic factors. Regul Pept 2000, 90:19-25.
5. Sundaresan M, Yu ZX, Ferrans VJ, et al.: Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science 1995, 270:296-299.
6. Griendling KK, Sorescu D, Ushio-Fukai M: NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000, 86:494-501.
7. Molavi B, Chen H, Mehta JL: Preservation of left ventricular function following ischemia-reperfusion by PPAR-γ ligands. Circulation 2003, 106:934.
8. Molavi B: Cardioprotective effects of rosiglitazone against ischemia-reperfusion injury are associated with modulation of angiotensin receptor expression and signaling. J Am Coll Cardiol 2004, 5:305A.
9. Griendling KKP, FitzGerald GAM: Oxidative stress and cardiovascular injury: part ii: animal and human studies. Circulation 2003, 108:2034-2040. This is a detailed examination of the current evidence from animal and human studies of the role of ROS in cardiovascular disease.
10. Marczin N, El Habashi N, Hoare GS, et al.: Antioxidants in myocardial ischemia-reperfusion injury: therapeutic potential and basic mechanisms. Arch Biochem Biophys 2003, 420:222-236. This is a comprehensive review of the ischemia-reperfusion injury that focuses on the role of NF-κB.
11. Altavilla D, Deodato B, Campo GM, et al.: IRFI 042, a novel dual vitamin E-like antioxidant, inhibits activation of nuclear factor-kappaB and reduces the inflammatory response in myocardial ischemia-reperfusion injury. Cardiovasc Res 2000, 47:515-528.
12. Izumi T, Saito V, Kishimoto I, et al.: Blockade of the natriuretic peptide receptor guanylyl cyclase-A inhibits NF-kappaB activation and alleviates myocardial ischemia/reperfusion injury. J Clin Invest 2001, 108:203-213.
13. Reiter RJ, Tan DX: Melatonin: a novel protective agent against oxidative injury of the ischemic/reperfused heart. Cardiovasc Res 2003, 58:10-19.
14. Wilson EM, Moainie SL, Baskin JM, et al.: Region-and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation 2003, 107:2857-2863.
15. Spinale FG: Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 2002, 90:520-530.
16. Shiomi TM, Tsutsui HM, Matsusaka HM, et al.: Overexpression of glutathione peroxidase prevents left ventricular remodeling and failure after myocardial infarction in mice. Circulation 2004, 109:544-549.
17. Kinugawa S, Tsutsui H, Hayashidani S, et al.: Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: role of oxidative stress. Circ Res 2000, 87:392-398.
18. Chen J, Li D, Zhang X, Mehta JL: Tumor necrosis factor-alpha-induced apoptosis of human coronary artery endothelial cells: modulation by the peroxisome proliferator-activated receptor-gamma ligand pioglitazone. Journal of Cardiovascular Pharmacology & Therapeutics 2004, 9:35-41.
19. 18a Coviello JSMA, Nystrom KVM: Obesity and heart failure. J Cardiovasc Nurs 2003, 18:360-368.
20. Linger RH: Lipotoxic diseases. Annu Rev Med 2002, 53:319-336.
21. Therond P, Bonnefont-Rousselot D, Davit-Spraul A, et al.: Biomarkers of oxidative stress: an analytical approach. Curr Opin Clin Nutr Metab Care 2000, 3:373-384.
22. Ghiselli A, Serafini M, Maiani G, et al.: A fluorescence-based method for measuring total plasma antioxidant capability. Free Rad Biol Med 1995, 18:29-36.
23. Benzie IF, Strain JJ: Ferric reducing/antioxidant power assay: direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration. Methods Enzymol 1999, 299:15-27.
24. Holvoet P, Van Cleemput J, Collen D, et al.: Oxidized low density lipoprotein is a prognostic marker of transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol 2000, 20:698-702.
25. Hennekens CH, Buring JE, Manson JE, et al.: Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996, 334:1145-1149.
26. Yusuf S, Dagenais G, Pogue J, et al.: Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study investigators. N Engl J Med 2000, 342:154-160.